Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.
about
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancieszeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia.Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Contribution of bone microenvironment to leukemogenesis and leukemia progression.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy.Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesPhiladelphia chromosome-positive acute lymphoblastic leukemia.Molecular therapies for tuberous sclerosis and neurofibromatosis.Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
P2860
Q26829652-8EA5DA58-1383-4D75-875B-7053EF65BB36Q33526754-ABCD7890-5018-4138-A25C-A8AD1719FF33Q33783145-F0E60463-7264-4DD1-B246-8C774CCA6C8EQ33843477-4E6661E9-DDC3-46F7-BBDB-F08EE62D65CBQ35037058-F1329A81-5500-4E86-969A-D27BB8A94470Q35740894-25CCB800-D1B0-42B3-AC7D-6C59E03D4FF9Q35805960-91696911-7C5F-49B2-A918-9088ED888CB0Q36141916-31ED08BF-69C7-430A-91A8-54A82099A7E7Q37331742-DDEE56F4-094B-4AC1-907B-60DB28CF0C51Q37432231-F4FD002C-2F45-4552-B81C-AC8742FE7C65Q37613888-A9E4C1A4-8F80-4E75-91C3-E09FCB3A7B84Q38006431-D70EE512-B60D-44DC-A944-5DA6CF267666Q39119297-095BE15F-71C0-4C68-82E1-4B7DE4A4646AQ39478334-854CE98A-D44D-4B98-A8B3-FB1CADA4B679Q41241688-626D0992-F213-48C5-8E71-6A5108E29DE5
P2860
Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel molecular and cellular t ...... d lymphoproliferative disease.
@en
Novel molecular and cellular t ...... d lymphoproliferative disease.
@nl
type
label
Novel molecular and cellular t ...... d lymphoproliferative disease.
@en
Novel molecular and cellular t ...... d lymphoproliferative disease.
@nl
prefLabel
Novel molecular and cellular t ...... d lymphoproliferative disease.
@en
Novel molecular and cellular t ...... d lymphoproliferative disease.
@nl
P2093
P2860
P1433
P1476
Novel molecular and cellular t ...... d lymphoproliferative disease.
@en
P2093
Alix E Seif
David T Teachey
Gregor S D Reid
Stephan A Grupp
Valerie I Brown
P2860
P2888
P304
P356
10.1007/S12026-008-8038-9
P577
2008-01-01T00:00:00Z